Gabriele Picco
@gabrielepicco.bsky.social
Senior Staff Scientist @sangerinstitute.
Passionate about cancer genetics, functional genomics and precision medicine. Husband of one. Daddy of two.
Passionate about cancer genetics, functional genomics and precision medicine. Husband of one. Daddy of two.
Reposted by Gabriele Picco
We had the 3rd meeting of the UK EOCRC Research Consortium in beautiful Edinburgh yesterday supported by British Society of Gastroenterology (BSG) and @bowelcanceruk.bsky.social attended by over 50 UK academics - celebrating our first project funding success only 1 year after foundation
November 12, 2025 at 6:37 AM
We had the 3rd meeting of the UK EOCRC Research Consortium in beautiful Edinburgh yesterday supported by British Society of Gastroenterology (BSG) and @bowelcanceruk.bsky.social attended by over 50 UK academics - celebrating our first project funding success only 1 year after foundation
Reposted by Gabriele Picco
Very cool story and especially useful mathematical models for everyone to use! Check it out!!!
Using barcodes 📊 to track cancer 💊 resistance evolution: is it clonal selection or plasticity? @fwhiting.bsky.social knows! His new "Evolutionary Informed Resistance Assays" (EIRAs) framework infers resistance evolution dynamics from barcode diversity data. www.nature.com/articles/s41... @icr.ac.uk
Quantitative measurement of phenotype dynamics during cancer drug resistance evolution using genetic barcoding - Nature Communications
Understanding the dynamics of how drug resistance originates in cancer remains crucial, but it is not possible to observe them directly. Here, the authors construct a mathematical framework to infer d...
www.nature.com
June 20, 2025 at 2:38 PM
Very cool story and especially useful mathematical models for everyone to use! Check it out!!!
Reposted by Gabriele Picco
New @natgenet.nature.com paper from the brilliant @eszterlakatos.bsky.social presents evidence that chromatin alterations disrupt antigen presentation & neoantigens in colorectal cancer. Also that immune escape is part of the "Big Bang", at the outset of CRC growth. www.nature.com/articles/s41...
Epigenetically driven and early immune evasion in colorectal cancer evolution - Nature Genetics
This study nominates immune escape as an early event in colorectal cancer and shows how this can be driven through both genetic and epigenetic changes.
www.nature.com
November 5, 2025 at 4:36 PM
New @natgenet.nature.com paper from the brilliant @eszterlakatos.bsky.social presents evidence that chromatin alterations disrupt antigen presentation & neoantigens in colorectal cancer. Also that immune escape is part of the "Big Bang", at the outset of CRC growth. www.nature.com/articles/s41...
Thanks Isabelle. Wonderful experience presenting our work @mgarnett.bsky.social #genomicsatscale25! Thanks for having me!
Gabriele Picco @gabrielepicco.bsky.social from the Sanger Institute at #GenomicsAtScale25 @genscale.bsky.social
October 26, 2025 at 3:00 PM
Thanks Isabelle. Wonderful experience presenting our work @mgarnett.bsky.social #genomicsatscale25! Thanks for having me!
Reposted by Gabriele Picco
Our latest work is out in Nature today. In this paper, we introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people www.nature.com/articles/s41...
Somatic mutation and selection at population scale - Nature
A new version of nanorate DNA sequencing, with an error rate lower than five errors per billion base pairs and compatible with whole-exome and targeted capture, enables epidemiological-scale studies of somatic mutation and selection and the generation of high-resolution selection maps across coding and non-coding sites for many genes.
www.nature.com
October 8, 2025 at 4:31 PM
Our latest work is out in Nature today. In this paper, we introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people www.nature.com/articles/s41...
Reposted by Gabriele Picco
I'm very pleased to announce the official publication of our lab's paper "DNA mutagenesis driven by transcription factor competition with mismatch repair" in today's issue of Cell! www.cell.com/cell/abstrac...
DNA mutagenesis driven by transcription factor competition with mismatch repair
Competition between transcription factors and mismatch repair machinery drives localized
hypermutation at regulatory elements, with implications for cancer and genome evolution.
www.cell.com
October 2, 2025 at 11:37 PM
I'm very pleased to announce the official publication of our lab's paper "DNA mutagenesis driven by transcription factor competition with mismatch repair" in today's issue of Cell! www.cell.com/cell/abstrac...
Reposted by Gabriele Picco
The Garnett Lab is excited to launch DepMap Miner, a new tool to explore cancer dependency data!
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
September 20, 2025 at 7:43 AM
The Garnett Lab is excited to launch DepMap Miner, a new tool to explore cancer dependency data!
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
Reposted by Gabriele Picco
new out in Nature www.nature.com/articles/s41...
Fluctuating DNA methylation tracks cancer evolution at clinical scale - Nature
Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.
www.nature.com
September 11, 2025 at 7:34 AM
new out in Nature www.nature.com/articles/s41...
Reposted by Gabriele Picco
Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer - Nature
A single-cell sequencing study using more than 30,000 tumour genomes from human ovarian cancers shows that whole-genome doubling is an ongoing mutational process that drives tumour evolution and disru...
www.nature.com
July 17, 2025 at 8:24 AM
Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team
Reposted by Gabriele Picco
www.nature.com/articles/s41...
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature Genetics
The paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism.
www.nature.com
July 4, 2025 at 11:11 AM
www.nature.com/articles/s41...
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers
Reposted by Gabriele Picco
On behalf of InSiGHT, we are delighted to welcome you to the #InSiGHT2026 meeting in Singapore, taking place from 4 – 7 March 2026 #LynchSyndrome #Polyposis @cgaigc.com @stmarksgenomics.bsky.social
insight2026.org
insight2026.org
InSIGHT 2026
REGISTRATION NOW OPEN Register NowCall for Abstracts Now Open! Submit Your AbstractWelcome MessageWelcome to Singapore, Selamat Datang, 欢迎, வருக வருக. On behalf of InSIGHT, we are delighted to invite....
insight2026.org
June 10, 2025 at 6:28 PM
On behalf of InSiGHT, we are delighted to welcome you to the #InSiGHT2026 meeting in Singapore, taking place from 4 – 7 March 2026 #LynchSyndrome #Polyposis @cgaigc.com @stmarksgenomics.bsky.social
insight2026.org
insight2026.org
Reposted by Gabriele Picco
Planning to apply for #research #funding from the ERC?
From the next application rounds, expect changes to the:
• proposal structure
• evaluation process
• extra funding you can request
• eligibility for Starting & Consolidator #Grants (from 2027)
More 👇 europa.eu/!RPHWvv
From the next application rounds, expect changes to the:
• proposal structure
• evaluation process
• extra funding you can request
• eligibility for Starting & Consolidator #Grants (from 2027)
More 👇 europa.eu/!RPHWvv
Changes to the 2026 and 2027 Work Programmes
With the launch of the competitions for grants under ERC Work Programme 2026 in July of this year, several changes to the submission of applications and the evaluation of proposals will apply. The mai...
europa.eu
June 2, 2025 at 10:02 AM
Planning to apply for #research #funding from the ERC?
From the next application rounds, expect changes to the:
• proposal structure
• evaluation process
• extra funding you can request
• eligibility for Starting & Consolidator #Grants (from 2027)
More 👇 europa.eu/!RPHWvv
From the next application rounds, expect changes to the:
• proposal structure
• evaluation process
• extra funding you can request
• eligibility for Starting & Consolidator #Grants (from 2027)
More 👇 europa.eu/!RPHWvv
Reposted by Gabriele Picco
🚨 Excited to share our latest preprint!
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor
BEstimate: a computational tool for the design and interpretation of CRISPR base editing experiments https://www.biorxiv.org/content/10.1101/2025.05.19.654892v1
May 22, 2025 at 1:21 PM
🚨 Excited to share our latest preprint!
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor
Reposted by Gabriele Picco
How does tumour heterogeneity arise? How can we predict cancer cell plasticity? In 2 new studies, we trace #glioblastoma heterogeneity to a spatial cancer cell trajectory w. multimodal cell atlassing bit.ly/4mkrWgs & predict plasticity w. snRNA/ATAC+deep learning bit.ly/3FbI6Ic 🧵
May 16, 2025 at 11:44 AM
How does tumour heterogeneity arise? How can we predict cancer cell plasticity? In 2 new studies, we trace #glioblastoma heterogeneity to a spatial cancer cell trajectory w. multimodal cell atlassing bit.ly/4mkrWgs & predict plasticity w. snRNA/ATAC+deep learning bit.ly/3FbI6Ic 🧵
Great to see WRN featured in the #AACR25 Special Session on 'Bringing Science to the Clinic: Overcoming Hurdles for Therapeutic Translation.' Grateful to Tim Yap for highlighting our past and ongoing work!
April 29, 2025 at 11:30 PM
Great to see WRN featured in the #AACR25 Special Session on 'Bringing Science to the Clinic: Overcoming Hurdles for Therapeutic Translation.' Grateful to Tim Yap for highlighting our past and ongoing work!
Great talk by Yanhua Rao at #AACR2025 on GSK’s new clinical WRN inhibitor. Proud to see our unpublished data spotlighted for revealing new MoA insights. Exciting times ahead! @mgarnett.bsky.social
April 28, 2025 at 6:16 PM
Great talk by Yanhua Rao at #AACR2025 on GSK’s new clinical WRN inhibitor. Proud to see our unpublished data spotlighted for revealing new MoA insights. Exciting times ahead! @mgarnett.bsky.social
A fantastic collaboration with Emile Voest’s lab at NKI, the new @mattcoelho.bsky.social group. WG CRISPR screens in MSI organoids co-cultured with autologous reactive T cells! Amazing work from Alex Watterson! New preprint here: www.biorxiv.org/content/10.1...
#Organoids #Immunotherapy #CRISPR #MSI
#Organoids #Immunotherapy #CRISPR #MSI
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance
Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...
www.biorxiv.org
April 25, 2025 at 4:53 PM
A fantastic collaboration with Emile Voest’s lab at NKI, the new @mattcoelho.bsky.social group. WG CRISPR screens in MSI organoids co-cultured with autologous reactive T cells! Amazing work from Alex Watterson! New preprint here: www.biorxiv.org/content/10.1...
#Organoids #Immunotherapy #CRISPR #MSI
#Organoids #Immunotherapy #CRISPR #MSI
Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality
April 25, 2025 at 4:02 PM
Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality
Reposted by Gabriele Picco
Promising early safety and immunogenicity data from the Nous-209 Lynch Syndrome vaccine presented at AACR this month aacrjournals.org/cancerres/ar...
Abstract 6427: Nous-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers
Abstract. Cancer interception represents a new approach, aimed at targeting precancerous lesions and therefore preventing cancer occurrence. Lynch syndrome (LS) is one of the most prevalent hereditary...
aacrjournals.org
April 25, 2025 at 5:31 AM
Promising early safety and immunogenicity data from the Nous-209 Lynch Syndrome vaccine presented at AACR this month aacrjournals.org/cancerres/ar...
Reposted by Gabriele Picco
Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance
Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...
www.biorxiv.org
April 22, 2025 at 7:56 AM
Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
Quando torno in Italia, mi chiedono spesso: "Di cosa ti occupi adesso?" o "A che punto siamo con la cura del cancro?" Domande semplici, risposte complesse – spesso taglio corto.
March 24, 2025 at 11:55 PM
Quando torno in Italia, mi chiedono spesso: "Di cosa ti occupi adesso?" o "A che punto siamo con la cura del cancro?" Domande semplici, risposte complesse – spesso taglio corto.
Reposted by Gabriele Picco
Please forward to any interested scientists - we're looking for a scientist to work in our functional genomics centre to find new cancer targets in Cambridge, UK. A mix of wet lab as well as computational skills a plus.
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
Senior scientist – functional genomics
Senior scientist – functional genomics Location: Cambridge Salary: Competitive About AstraZeneca AstraZeneca is a global, science-led, and patient-focused biopharmaceutical company that focuses on the...
astrazeneca.wd3.myworkdayjobs.com
March 6, 2025 at 5:24 PM
Please forward to any interested scientists - we're looking for a scientist to work in our functional genomics centre to find new cancer targets in Cambridge, UK. A mix of wet lab as well as computational skills a plus.
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
Reposted by Gabriele Picco
Now online in Cancer Discovery: Single-Cell eQTL Mapping Reveals Cell Subtype-Specific Genetic Control and Mechanism in Malignant Transformation of Colorectal Cancer - by Can Chen, Yimin Cai, Wenlong Hu, Kai Tan, Zequn Lu, Xuanyu Zhu, Jianbo Tian, Xiaoping Miao & colleagues doi.org/10.1158/2159...
March 4, 2025 at 4:11 PM
Now online in Cancer Discovery: Single-Cell eQTL Mapping Reveals Cell Subtype-Specific Genetic Control and Mechanism in Malignant Transformation of Colorectal Cancer - by Can Chen, Yimin Cai, Wenlong Hu, Kai Tan, Zequn Lu, Xuanyu Zhu, Jianbo Tian, Xiaoping Miao & colleagues doi.org/10.1158/2159...
Reposted by Gabriele Picco
Work led by Syed Haider and our team at the @breastcancernow.bsky Toby Robins Research Centre @icr.ac.uk and funded by @cancerresearchuk.org
We show transcriptomic buffering of tumour suppressor loss via syn. lethal genes is not anecdotal but a cancer hallmark. Buffering also seen in BRCAness, predicts penetrant syn leth effects and outcome. @icr.ac.uk @cancerresearchuk.org @breastcancernow.bsky.social www.nature.com/articles/s41...
The transcriptomic architecture of common cancers reflects synthetic lethal interactions - Nature Genetics
Tumor cells upregulate compensatory buffering genes following tumor suppressor loss. These genes may represent new synthetic lethal partners that could be harnessed therapeutically.
www.nature.com
March 3, 2025 at 11:17 AM
Work led by Syed Haider and our team at the @breastcancernow.bsky Toby Robins Research Centre @icr.ac.uk and funded by @cancerresearchuk.org
Reposted by Gabriele Picco
Today in BJC Reports, we summarise the outcomes from a multidisciplinary workshop focused on addressing cancer drug resistance.
www.nature.com/articles/s44...
www.nature.com/articles/s44...
Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance - BJC Reports
BJC Reports - Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance
www.nature.com
February 28, 2025 at 9:21 AM
Today in BJC Reports, we summarise the outcomes from a multidisciplinary workshop focused on addressing cancer drug resistance.
www.nature.com/articles/s44...
www.nature.com/articles/s44...